![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PAX7 |
Gene summary for PAX7 |
![]() |
Gene information | Species | Human | Gene symbol | PAX7 | Gene ID | 5081 |
Gene name | paired box 7 | |
Gene Alias | HUP1 | |
Cytomap | 1p36.13 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P23759 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5081 | PAX7 | LP16 | Human | Oral cavity | LP | 5.89e-05 | 4.99e-01 | 0.1055 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAX7 | SNV | Missense_Mutation | c.685C>A | p.Leu229Met | p.L229M | P23759 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PAX7 | SNV | Missense_Mutation | novel | c.880C>G | p.Pro294Ala | p.P294A | P23759 | protein_coding | tolerated(0.08) | benign(0.311) | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PAX7 | SNV | Missense_Mutation | novel | c.166C>T | p.Arg56Cys | p.R56C | P23759 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PAX7 | SNV | Missense_Mutation | rs774565338 | c.329C>T | p.Ala110Val | p.A110V | P23759 | protein_coding | deleterious(0.03) | possibly_damaging(0.555) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PAX7 | SNV | Missense_Mutation | c.1376G>A | p.Gly459Asp | p.G459D | P23759 | protein_coding | deleterious_low_confidence(0) | benign(0.382) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PAX7 | SNV | Missense_Mutation | rs768503948 | c.817N>T | p.Arg273Cys | p.R273C | P23759 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PAX7 | SNV | Missense_Mutation | novel | c.34A>G | p.Met12Val | p.M12V | P23759 | protein_coding | tolerated_low_confidence(0.11) | benign(0.007) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAX7 | SNV | Missense_Mutation | novel | c.850T>G | p.Phe284Val | p.F284V | P23759 | protein_coding | tolerated(0.1) | probably_damaging(0.917) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PAX7 | SNV | Missense_Mutation | c.580N>T | p.Asp194Tyr | p.D194Y | P23759 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-DM-A0XF-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | mayo | CR | |
PAX7 | SNV | Missense_Mutation | c.896N>T | p.Thr299Met | p.T299M | P23759 | protein_coding | deleterious(0.01) | possibly_damaging(0.776) | TCGA-DM-A0XF-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | mayo | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |